



Modified Form 1449/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/743,563
	Filing Date	December 22, 2003
	First Named Inventor	Charrier et al.
	Group Art Unit	1625
	Examiner Name	Zinna Northington Davis
	Attorney Docket Number	VPI/02-131 US

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
[Handwritten arrow pointing down]	A1	5,756,466	26-May-1998	Bemis et al.			
	A2	4,728,647	1-Mar-1988	Benavides, et al.			
	A3	5,656,627	12-Aug-1997	Bemis et al.			
	A4	5,847,135	08-Dec-1998	Bemis et al.			
	A5	5,716,929	10-Feb-1998	Bemis et al.			
	A6	6,103,711	15-Aug-2000	Bemis et al.			
	A7	5,973,111	26-Oct-1999	Bemis et al.			
	A8	6,420,522	16-Jul-2002	Bemis et al.			
	A9	6,025,147	15-Feb-2000	Bemis et al.			
	A10	20030162993	28-Aug-2003	Mortimore et al.			
	A11	20040019017	29-Jan-2004	Mortimore et al.			

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number		Name of Patentee(s) or Applicant(s)	Date of Publication	Translation	
						Yes	No
[Handwritten arrow pointing down]	B1	WO	98/16502 A1	Warner-Lambert Company	23-Apr-1998		
	B2	WO	98/16505 A1	Warner-Lambert Company	23-Apr-1998		
	B3	WO	96/40647 A1	Prototek Inc.	19-Dec-1996		
	B4	WO	98/18781A2	Versicor Inc.	07-May-1998		
	B5	WO	2000/68188 A1	Texas Biotechnology Corporation	16-Nov-2000		
	B6	WO	2004/058718 A1	Vertex Pharmaceuticals Incorporated	15-July-2004		
	B7	WO	2004/002961 A1	Vertex Pharmaceuticals Incorporated	08-Jan-2004		
	B8	DD	232699 A1	Akademie der Wissenschaften der	5-Feb-1986		X

OTHER NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
[Handwritten arrow pointing down]	C1	Semple, G., et al. "Pyridone-Based Peptidomimetic Inhibitors of Interleukin-1 β -Converting Enzyme (ICE)," <i>Bioorganic & Medicinal Chem. Letters</i> , 7(10):1337-1342 (1997).
	C2	Livingston, D.J. "In Vitro and In Vivo Studies of Ice Inhibitors," <i>J. of Cell. Biochem.</i> , 64(1):19-26 (1997).
	C3	Husain, M. I., et al. "Some New 2-Aryloxyethyl-3-alpha-substituted Carboxymethyl-6,8-substituted-4-Quinazolones As Possible Anticonvulsants," <i>Pharmazie</i> , 37(6):408-410 (1982).
	C4	Hussian, M., Imtiaz, et al. "Some Newer Quinazolones as Possible Anticonvulsants," <i>J. Chem. Soc. Pak</i> , 6(4):211-215 (1984).
	C5	Canon, P., et al. "Synthesis of chiral 3-substituted 2,4(1H,3H)-quinazolinodiones," <i>Heterocycles</i> , 36(6):1305-1314 (1993).
	C6	Gouilleux, L., et al. "Solid Phase Synthesis of Chiral 3-substituted Quinazoline-2, 4-diones," <i>Tetrahedron Letters</i> , 37(39):7031-7034 (1996).
	C7	Gordeev, M. F., et al. "A General and Efficient Solid Phase Synthesis of Quinazoline-2, 4-diones," <i>Tetrahedron Letters</i> , 38(10):1729-1732 (1997).
	C8	Prokai-Tatrai, K., et al., "Prodrugs to Enhance Central Nervous System Effects of TRH-like Peptide pGlu-Glu-Pro-NH ₂ ," <i>Bioorg. Med. Chem. Lett.</i> , 13:1011-1014 (2003).
	C9	Narasimhan, R. S., "Synthetic Application of Lithiation Reactions; IX. A Simplified Synthesis of Isocoumarin," <i>Synthesis</i> , 12: 797 (1975).
	C10	Kinder, M. A., et al., "Solid State Photochemistry of Isocoumarins and Isothiocoumarins," <i>Tetrahedron</i> 56: 6763-6767 (2000).
	C11	Revesz, L., et al., "Synthesis of P1 Aspartate-Based Peptide Acyloxymethyl and Fluoromethyl Ketones as Inhibitors of Interleukin-1 β -Converting Enzyme," <i>Tetrahedron Letters</i> , 35 (52):9693-9696 (1994).

Examiner Signature	<i>Zinna N Davis</i>	Date Considered	9/20/2006
--------------------	----------------------	-----------------	-----------

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications). EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. include copy of this form with next communication to applicant.